Ontology highlight
ABSTRACT:
SUBMITTER: Ribera JM
PROVIDER: S-EPMC4485855 | biostudies-literature | 2015
REPOSITORIES: biostudies-literature
Ribera Josep-Maria JM Ferrer Albert A Ribera Jordi J Genescà Eulàlia E
OncoTargets and therapy 20150624
The CD19 marker is expressed on the surface of normal and malignant immature or mature B-cells. On the other hand, immunotherapy involving T-cells is a promising modality of treatment for many neoplastic diseases including leukemias and lymphomas. The CD19/CD3-bispecific T-cell-engaging (BiTE(®)) monoclonal antibody blinatumomab can transiently engage cytotoxic T-cells to CD19+ target B-cells inducing serial perforin-mediated lysis. In the first clinical trial, blinatumomab showed efficacy in no ...[more]